*2.1. Study Design*

NCT02956226 was a proof-of-concept, randomized, double-blind, placebo-controlled trial, and methods were previously described [23]. The primary objective of this trial was to assess the impact of cannabinoid treatment on ASD-associated disruptive behavior. We previously reported the effects of the cannabinoid treatment on disruptive behavior and the ASD core symptoms, as well as adverse effects of the treatment [23]. We report here the effect of the cannabinoid treatment on sleep parameters.

#### *2.2. Standard Protocol Approvals and Patient Consent*

The study was conducted in a single referral center for ASD diagnosis and treatment: Shaare Zedek Medical Center, Jerusalem, Israel. It was approved by the Institutional Review Board at Shaare Zedek Medical Center and the Israeli Ministry of Health prior to participant enrollment. Participants' parents provided written informed consent and written consent was also obtained from participants, when appropriate.
